ClinicalTrials.gg
CompletedNCT02219477TURQUOISE-CPBUpdated Jul 11, 2017Results posted

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir in Chronic Hepatitis C, Decompensated Cirrhosis and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ombitasvir/Paritaprevir/Ritonavir · Hepatitis C, Chronic.

Enrollment
6th of 10
36 · median 48
Started
2014
with 5 others
Phase 3
8 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
9 of 10
AbbVie

Among the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic, this one is the 6th largest by enrollment, is one of 6 that started in 2014, is one of 8 in phase 3, and was the 3rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

About Ombitasvir/Paritaprevir/Ritonavir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic as a file.
02

Study summary

The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.

03

Conditions studied

  • Chronic Hepatitis C
  • Decompensated Cirrhosis
  • Hepatitis C Virus

Keywords

  • Cirrhosis
  • Hepatitis C
  • Child-Pugh B
  • Hepatitis C Genotype 4
  • Interferon-Free
  • Hepatitis C Genotype 1
  • Chronic Hepatitis C
  • Decompensated Cirrhosis
  • Hepatitis C Virus
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. GT1- or GT4-infection defined as: positive for anti-HCV Ab, HCV RNA > 1,000 IU/mL and laboratory result indicating HCV GT1 or GT4 infection at Screening.
  2. Evidence of cirrhosis by prior liver , FibroScan or by radiograph (i.e., computed tomography [CT] scan or magnetic resonance imaging [MRI]).
  3. Score of 7 - 9, inclusive, at time of Screening.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Positive test result for surface antigen (HbsAg) or anti- antibodies (HIV Ab).
  3. Prior or current use of any other or commercially available anti- agents other than interferon/RBV and/or pegylated interferon (pegIFN)/RBV (including but not limited to telaprevir, boceprevir, sofosbuvir and simeprevir).
  4. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such as CT scan or MRI within 3 months prior to Screening or on an ultrasound performed at Screening (a positive ultrasound result will be confirmed with CT scan or MRI).
  5. Any current or past evidence of C classification.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1: GT1B

    ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants

    Drug: ombitasvir/paritaprevir/ritonavir · Drug: dasabuvir · Drug: ribavirin

  • Experimental
    Group 2: GT1 Non-B

    ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants

    Drug: ombitasvir/paritaprevir/ritonavir · Drug: dasabuvir · Drug: ribavirin

  • Experimental
    Group 3: GT4

    ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants

    Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin

Interventions

  • Drugombitasvir/paritaprevir/ritonavir

    Drug page: Ombitasvir/Paritaprevir/Ritonavir

    tablet; paritaprevir co-formulated with ritonavir and ombitasvir

    Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as norvir

  • tablet

    Also known as: ABT-333

  • tablet

06

What researchers measure

Primary outcomes

  1. Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2

    SVR12, defined as HCV RNA \< lower limit of quantification (LLOQ) in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures. The 95% confidence interval was calculated using the Wilson score method.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With SVR12 in Group 3

    SVR12, defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit, who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures.

    Time frame: 12 weeks after the last actual dose of study drug

  2. Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure

    On-treatment virologic failure was defined as: confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \> 1 log˅10 IU/mL above nadir) at any time point during treatment; or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment. The 95% confidence interval was calculated using Wilson score method. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window.

    Time frame: Up to 24 weeks during treatment

  3. Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12

    Relapse˅12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of active study drug (up to and including the SVR12 window) for a participant with HCV RNA \< LLOQ at final treatment visit who completes treatment and has post-treatment HCV RNA data. Completion of treatment was defined as a study drug duration ≥ 77 days for participants assigned to 12 weeks of treatment or ≥ 154 days for participants assigned to 24 weeks of treatment. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% confidence interval was calculated using the Wilson score method.

    Time frame: Up to 12 weeks after the last actual dose of study drug

  4. Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests

    Improvement was defined as: * increase of more than 0.2 g/L from baseline to post-treatment Week 12 in albumin * decrease of more than 0.3 µmol/L from baseline to post-treatment Week 12 in bilirubin * decrease of more than 5 ng/mL from baseline to post-treatment Week 12 in alpha-fetoprotein * increase of more than 15\*10\^9/L from baseline to post-treatment Week 12 in platelet count * decrease of more than 0.2 from baseline to post-treatment Week 12 in international normalized ratio.

    Time frame: Up to post-treatment Week 12

  5. Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest

    The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Improvement was defined as a decrease of more than 0.2 from baseline to post-treatment Week 12.

    Time frame: Up to post-treatment Week 12

  6. Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score

    The The Child-Pugh score uses five clinical measures of liver disease (3 laboratory parameters and 2 clinical assessments) to measure severity of cirrhosis. Scores range from 5 to 15, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.

    Time frame: Up to post-treatment Week 12

  7. Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score

    MELD is a scoring system for assessing the severity of chronic liver disease. Scores range from 6 to 40, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.

    Time frame: Up to post-treatment Week 12

07

Results

Posted Jul 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Started9243
Completed9222
Not completed021
Withdrew: Adverse event011
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryPercentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2

SVR12, defined as HCV RNA \< lower limit of quantification (LLOQ) in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures. The 95% confidence interval was calculated using the Wilson score method.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-B
Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2100 (70.1 to 100.0)95.8 (79.8 to 99.3)
SecondaryPercentage of Participants With SVR12 in Group 3

SVR12, defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit, who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With SVR12 in Group 3
percentage of participantsGroup 3: GT4
Percentage of Participants With SVR12 in Group 366.7
SecondaryPercentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure

On-treatment virologic failure was defined as: confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \> 1 log˅10 IU/mL above nadir) at any time point during treatment; or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment. The 95% confidence interval was calculated using Wilson score method. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window.

Time frame:
Up to 24 weeks during treatment
Reported as:
Number · percentage of participants
Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure0 (0.0 to 29.9)0 (0.0 to 13.8)0 (NA to NA)
SecondaryPercentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12

Relapse˅12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of active study drug (up to and including the SVR12 window) for a participant with HCV RNA \< LLOQ at final treatment visit who completes treatment and has post-treatment HCV RNA data. Completion of treatment was defined as a study drug duration ≥ 77 days for participants assigned to 12 weeks of treatment or ≥ 154 days for participants assigned to 24 weeks of treatment. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% confidence interval was calculated using the Wilson score method.

Time frame:
Up to 12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅120 (0.0 to 35.4)0 (0.0 to 16.8)0 (NA to NA)
SecondaryPercentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests

Improvement was defined as: * increase of more than 0.2 g/L from baseline to post-treatment Week 12 in albumin * decrease of more than 0.3 µmol/L from baseline to post-treatment Week 12 in bilirubin * decrease of more than 5 ng/mL from baseline to post-treatment Week 12 in alpha-fetoprotein * increase of more than 15\*10\^9/L from baseline to post-treatment Week 12 in platelet count * decrease of more than 0.2 from baseline to post-treatment Week 12 in international normalized ratio.

Time frame:
Up to post-treatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Albumin77.877.350.0
Bilirubin66.772.7100
Alpha-fetoprotein33.3——
Platelet count22.214.30
International normalized ratio000
SecondaryPercentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest

The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Improvement was defined as a decrease of more than 0.2 from baseline to post-treatment Week 12.

Time frame:
Up to post-treatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest09.150.0
SecondaryPercentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score

The The Child-Pugh score uses five clinical measures of liver disease (3 laboratory parameters and 2 clinical assessments) to measure severity of cirrhosis. Scores range from 5 to 15, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.

Time frame:
Up to post-treatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score66.754.550.0
SecondaryPercentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score

MELD is a scoring system for assessing the severity of chronic liver disease. Scores range from 6 to 40, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.

Time frame:
Up to post-treatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score
percentage of participantsGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score87.561.9100

Adverse events

Collected over Protocol-related treatment-emergent adverse events and treatment-emergent serious adverse events were collected from the first dose of study drug until post treatment Day 30; treatment was up to Week 12 for Group 1, and up to Week 24 for Groups 2 and 3.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: GT1B—1/9 (11.1%)8/9 (88.9%)
Group 2: GT1 Non-B—10/24 (41.7%)24/24 (100%)
Group 3: GT4—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
ASCITESGastrointestinal disorders1/91/241/3
DIARRHOEAGastrointestinal disorders0/90/241/3
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders0/90/241/3
HEPATIC FAILUREHepatobiliary disorders0/90/241/3
HYPERBILIRUBINAEMIAHepatobiliary disorders1/91/241/3
ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications0/90/241/3
DEHYDRATIONMetabolism and nutrition disorders0/91/241/3
ELECTROLYTE IMBALANCEMetabolism and nutrition disorders0/90/241/3
HYPONATRAEMIAMetabolism and nutrition disorders0/91/241/3
HEPATIC ENCEPHALOPATHYNervous system disorders0/92/241/3
Most frequent other events
Showing 10 of 74
Most frequent other events
EventGroup 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4
ABDOMINAL PAINGastrointestinal disorders0/93/243/3
NAUSEAGastrointestinal disorders2/913/242/3
FATIGUEGeneral disorders3/911/242/3
DIZZINESSNervous system disorders1/97/242/3
INSOMNIAPsychiatric disorders0/96/242/3
PANIC ATTACKPsychiatric disorders0/90/242/3
DIARRHOEAGastrointestinal disorders3/910/241/3
LEUKOCYTOSISBlood and lymphatic system disorders0/90/241/3
ABDOMINAL PAIN UPPERGastrointestinal disorders0/93/241/3
ASCITESGastrointestinal disorders0/98/241/3

Baseline characteristics

Age, Customized
Age, Customized(Participants)Group 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4Total
< 65 years720229
>= 65 years2417
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: GT1BGroup 2: GT1 Non-BGroup 3: GT4Total
Female27110
Male717226
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jun 2016, 18 months.

Results were first posted in Jul 2017, 1 year after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2014
First posted
Aug 19, 2014
StartActual
Nov 24, 2014
Primary completionActual
Jun 13, 2016
CompletionActual
Mar 3, 2017
Results first posted
Jul 11, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02219477
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 19, 2014
Start date
Nov 24, 2014
Primary completion
Jun 13, 2016
Completion
Mar 3, 2017
Results posted
Jul 11, 2017
Last update
Jul 11, 2017

Study contacts

Eric Cohen, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir/Paritaprevir/Ritonavir · Ribavirin

Start the discussion